Adjuvant systemic therapy of gastrointestinal stromal tumors: The Scandinavian Sarcoma Group perspective.
Gastrointestinal stromal tumors (GISTs) have a malignant potential varying from virtually no risk of recurrence (microscopic GISTs) to a high risk. Acquired secondary mutations that interfere with imatinib binding have been identified as a common mechanism for drug resistance and tumor progression i...
| Publicado en: | Acta Orthopaedica (Supplement) Vol. 80; pp. 37 - 44 |
|---|---|
| Autores principales: | , |
| Formato: | tables/charts Journal Article |
| Publicado: |
Medical Journals Sweden AB
Apr2009 Supplement 334
|
| Acceso en línea: | Ver este registro en EBSCOhost |